Trial reportBreast cancer research and treatment2010
Prognostic and predictive impact of central necrosis and fibrosis in early breast cancer: results from two International Breast Cancer Study Group randomized trials of chemoendocrine adjuvant therapy.
Trial report in Breast cancer research and treatment, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 54 citations in OpenAlex.
- Machine Learning Enabled Photoacoustic Spectroscopy for Noninvasive Assessment of Breast Tumor ProgressionACS sensors · 2024Article
- Extensively infarcted breast cancer.BMJ case reports · 2023Article
- Prognostic value of tumor necrosis based on the evaluation of frequency in invasive breast cancer.BMC cancer · 2023Article
- Myeloid MyD88 restricts CD8Scientific reports · 2023Article
- Tumor budding and fibrotic focus-proposed grading system for tumor budding in invasive carcinoma no special type of the breast.Virchows Archiv : an international journal of pathology · 2022Article
- Article
- Tumor Microenvironment in Breast Cancer-Updates on Therapeutic Implications and Pathologic Assessment.Cancers · 2021Review
- The Influence of the Exclusion of Central Necrosis on [Diagnostics (Basel, Switzerland) · 2021Article
- Defining Immunogenic and Radioimmunogenic Tumors.Frontiers in oncology · 2021Review
- Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?European radiology · 2020Article
- Macropinocytosis confers resistance to therapies targeting cancer anabolism.Nature communications · 2020Article
- Oxygen-sensitive MRI assessment of tumor response to hypoxic gas breathing challenge.NMR in biomedicine · 2019Article
- Article
- Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity.International review of cell and molecular biology · 2019Review
- Association among T2 signal intensity, necrosis, ADC and Ki-67 in estrogen receptor-positive and HER2-negative invasive ductal carcinoma.Magnetic resonance imaging · 2018Article
- Limited fibrosis accompanies triple-negative breast cancer metastasis in multiple model systems and is not a preventive target.Oncotarget · 2018Article
- Article
- Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers.Cancer management and research · 2018Review
- Pre-clinical Evaluation of a Cyanine-Based SPECT Probe for Multimodal Tumor Necrosis Imaging.Molecular imaging and biology · 2016Article
- The Necrosis-Avid Small Molecule HQ4-DTPA as a Multimodal Imaging Agent for Monitoring Radiation Therapy-Induced Tumor Cell Death.Frontiers in oncology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 4 countries.
Funding
Abstract
A minority of early invasive breast cancers show a pattern of central necrosis and fibrosis (CNF). Previous studies have documented an adverse prognostic impact and association with other adverse pathological features, but its predictive importance for therapy selection is unknown. We examined the prognostic and predictive value of CNF in two randomized clinical trials comparing chemoendocrine therapy with endocrine therapy alone in patients with node-negative breast cancer. A total of 1,850 patients randomly assigned to treatment groups comparing endocrine with chemoendocrine therapy, and with centrally-assessed CNF, ER, PgR and HER2 were included in the analytic cohort. The median follow up was 10 years. CNF was present in 84 of 1,850 trial patients (4.5%). It was associated with tumor characteristics suggesting poor outcome, but was an independent adverse factor for disease-free survival. In the presence of CNF outcome was worse regardless of tumor grade, whereas in the absence of CNF, patients with grade 3 tumors had poorer outcome than those with grade 1-2 tumors. Among patients with estrogen receptor-absent tumors chemoendocrine therapy was superior to endocrine therapy alone only in the absence of CNF [HR (chemoendocrine:endocrine) = 0.46 in CNF-absent, 0.90 in CNF-present], while among those with receptor-positive disease chemoendocrine therapy was beneficial only in the presence of CNF [HR = 0.34 CNF-present, 0.96 CNF-absent]. The results suggest that the presence of CNF reflects a biological difference in early breast cancer that is important in modulating the efficacy of standard therapies. Accordingly we believe that its presence should be routinely reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.